Analyst Josh Jennings of TD Cowen maintained a Buy rating on Cerus, retaining the price target of $5.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Josh Jennings’s rating is based on Cerus’s impressive financial performance and strategic advancements. The company reported record product revenues that exceeded market expectations, demonstrating robust growth across its INTERCEPT product line. This strong financial showing, along with an upward revision in 2025 sales guidance, underscores the sustainability of Cerus’s revenue growth, which is currently undervalued in the market.
Furthermore, Cerus’s continued expansion in the U.S. INTERCEPT platelet market and progress in clinical development programs highlight its strategic execution. The company’s advancements in technology, such as the next-gen INT200 LED illuminator, and successful clinical trials, align with its long-term vision of enhancing global blood supply safety. These factors, combined with positive customer feedback and operational efficiency, reinforce the company’s strong market position and future growth potential.
In another report released today, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $4.00 price target.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CERS in relation to earlier this year.